Transcripts fold change in differentiation.

<p>Green, red and black indicate transcripts that decrease, increase or maintain their concentration during induction respectively.</p

Immunophenotype of undifferentiated and differentiated cells.

<p>Immunofluorescence of undifferentiated GSCs neurosphere (left panels) and of differentiated cells (right panels) labelled with anti-human Sox2 (top panels), anti-human GFAP and anti-human TUBB3 (bottom panels).</p

Patients characteristics.

<p> =  sample identifier, sex  =  patient sex, KPS (score)  =  Karnofsky Performance Status score; Sympt. (mo)  =  symptom duration in month; Surgery (type)  =  origin of tumor tissue from the patient brain (temporal/parietal/occipital/frontal); ki67-%  = % of cells expressing ki-67; p53 =  p53 positivity (less than 5% of nuclei); MGMT  =  MGMT promoter metylation; EGFR  =  EGFR positivity (moderate-to-strong signal on >% of cells); PFS  =  progression-free survival; OS  =  overall survival; PTEN activ  =  PTEN activation group according to clustering of phospoproteomics profiles. Characteristics of patients from which samples were collected. Legend: Sample </p

Transcriptional and post-translational modulation of CDC25A, DUB3 and Wee1 during cell cycle in PTEN active cell lines.

<p>CDC25A mRNA is constantly produced throughout all phases while DUB3 expression increases in the G1/S phase and wee1 expression decreases during the phase M. CDC25A modulation occurs at post translational level with DUB3 inhibiting its ubiquitination and Wee1 controlling negatively the activity of Cyclin-B/Cdk1.</p